Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Enrolling by invitation · Phase 2
Conditions studied: Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric, T Cell Lymphoma
In brief
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
Key facts
- Study ID
- NCT03628612
- Run by
- Autolus Limited
- People needed
- 500
- Starts
- 2018-08-02
- Expected to finish
- 2043-12-01
- Last updated by the study team
- 2025-08-07
Who can join
Age: 1 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients must have received an AUTO CAR T cell therapy on a clinical treatment study.
- Patients must have provided informed consent for long-term follow-up study prior to participation.
- Patients must be able to comply with the study requirements.
You may not qualify if…
- There are no specific exclusion criteria for this study.
Where it is running
- University of Miami — Miami, Florida, United States
- Washington University in St. Louis — St Louis, Missouri, United States
- St David's South Austin Medical Center — Austin, Texas, United States
- Queen Elizabeth University Hospital — Glasgow, United Kingdom
- University College London Hospitals NHS Foundation Trust — London, United Kingdom
- Manchester Royal Infirmary Hospital — Manchester, United Kingdom
- Royal Manchester Children's Hospital — Manchester, United Kingdom
- Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust — Newcastle upon Tyne, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.